[1] WHITESIDE TL. FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity [J].Expert Opin Ther Targets,2018,22(4): 353-363. [2] QUE Y,XIAO W,GUAN YX,et al.PD-L1 expression is associated with FOXP3+ regulatory T-cell infiltration of soft tissue sarcoma and poor patient prognosis [J].J Cancer,2017,8(11): 2018-2025. [3] KITANO Y,OKABE H,YAMASHITA YI,et al.Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma [J].Br J Cancer,2018,118(2): 171-180. [4] PENG JZ,YU ZG,XUE L,et al.The effect of foxp3-overexpressing Treg cells on non-small cell lung cancer cells [J].Mol Med Rep,2018,17(4): 5860-5868. [5] SUN XW,FENG ZJ,WANG YX,et al.Expression of foxp3 and its prognostic significance in colorectal cancer [J].Int J Immunopathol Pharmacol,2017,30(2): 201-206. [6] BODUC M,ROESSLER M,MANDIC R,et al.Foxp3 expression in lymph node metastases in patients with head and neck cancer [J].Acta Otolaryngol,2017,137(11): 1215-1219. [7] SONG JJ,ZHAO SJ,FANG J,et al.Foxp3 overexpression in tumor cells predicts poor survival in oral squamous cell carcinoma [J].BMC Cancer,2016,16: 530. [8] DUAN XH,JIANG B,YANG JH,et al.FOXP3 inhibits MYC expression via regulating miR-198 and influences cell viability,proliferation and cell apoptosis in HepG2[J].Cancer Med,2018,7(12): 6182-6192. [9] LI XJ,GAO Y,LI JJ,et al.FOXP3 inhibits angiogenesis by downregulating VEGF in breast cancer [J].Cell Death Dis,2018,9(7): 744. [10] LI J P,LIAO X H,XIANG Y,et al.MKL1/miR34a/FOXP3 axis regulates cell proliferation in gastric cancer [J].J Cell Biochem,2019,120(5):7814-7824. [11] FU HY,LI C,YANG W,et al.FOXP3 and TLR4 protein expression are correlated in non-small cell lung cancer: implications for tumor progression and escape [J].Acta Histochem,2013,115(2): 151-157. [12] LI C,YANG W,GAI XD,et al.Foxp3 overexpression decreases sensitivity to chemotherapy in mouse Lewis lung cancer cells [J].Mol Med Rep,2012,6(5): 977-982. [13] EL-GENDI S,ABU-SHEASHA G.Ki-67 and cell cycle regulators p53,p63 and cyclind1 as prognostic markers for recurrence/progression of bladder urothelial carcinoma [J].Pathol Oncol Res,2018,24(2): 309-322. [14] HE Q,LI G L,JI X,et al.Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer [J].Tumour Biol,2017,39(5): 1010428317697571. [15] LI K,CHEN F C,XIE H J.Decreased FOXP3+ and GARP+ Tregs to neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer [J].Onco Targets Ther,2016,9: 3525-3533. [16] ROCHA C R R,SILVA M M,QUINET A,et al.DNA repair pathways and cisplatin resistance: an intimate relationship [J].Clinics (Sao Paulo),2018,73(suppl 1): e478s. [17] JAIN A,JAHAGIRDAR D,NILENDU P,et al.Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics [J].Expert Rev Anticancer Ther,2017,17(9): 815-825. [18] SHEN G H,MA H,PANG F W,et al.Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis [J].Acta Radiol,2018,59(2): 188-195. [19] HE L Y,ZHANG H,WANG Z K,et al.Diagnostic and prognostic significance of E-cadherin and Ki-67 expression in non-small cell lung cancer patients [J].Eur Rev Med Pharmacol Sci,2016,20(18): 3812-3817. [20] WEI D M,CHEN W J,MENG R M,et al.Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14732 patients [J].Respir Res,2018,19(1): 150. [21] YANG S C,LIU Y,LI M Y,et al.FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer [J].Mol Cancer,2017,16(1): 124. [22] 张志峰,席维岳.外周血肿瘤标志物早期诊断肺癌临床价值研究[J].中国实用内科杂志,2018,38(5):477-479. [23] 魏雨晴,吕镗烽,刘红兵,等.肺癌分子诊断及其研究进展[J].中国实用内科杂志,2019,39(5):407-411. |